Mediaboss Marketing

Thursday, July 7th 2022 - 09:54 UTC This is a big step forward that illustrates our ambitions towards the climate and biodiversity, said French Energy Transition ministeer, Agns Pannier-Runacher.

The European Council, the body that sets the political agenda of the European Union (EU), agreed on a proposal to limit the entry and trade of commodities where production has contributed to deforestation or forest degradation worldwide.

The agreement sets rules for operators who work with palm oil, beef, wood, coffee, cocoa, and soybeans, as well as certain derivatives such as leather, chocolate, and furniture.

We must ensure that the products we consume in Europe do not contribute to the depletion of the planets forests. The innovative text we have adopted will make it possible to fight deforestation in the EU and outside it. This is a big step forward that illustrates our ambitions towards the climate and biodiversity, said French Minister for Energy Transition, Agns Pannier-Runacher.

According to the European Council, EU political leaders also agreed to simplify and clarify the environmental due diligence system that governs commodity market activity. A comparative assessment system was also adopted, classifying the risk of deforestation for specific productions into three levels.

Other measures agreed on were regarding EU emissions trading system, emissions and removals from land use, land-use change, and forestry, the creation of a social climate fund (SCF) and new CO2 emission performance standards for cars and vans.

Among the most eye-catching measures are the addition of maritime shipping in the EU emissions trading system (ETS), the creation of a new, separate emissions trading system for the buildings and road transport sectors, the allocated 59 billion for the SCF, the overall objective to remove 310 million tons of CO2 equivalent by improving land and forestry use, and the end of the sale of combustion-engine cars by 2035.

Frans Timmermans, the Commission's Executive Vice-President for the European Green Deal, told reporters that it is a very good day for the European Green Deal, and a very good day for the European Union.

Read this article:
European Union gets tough on trade affecting deforestation and forest degradation - MercoPress

GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax,Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) for adolescents aged 12 through 17. The approval follows the positive recommendation made by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 23, 2022.

"With this authorization, we are extremely pleased to be able to offer our Nuvaxovid COVID-19 vaccine to adolescents in the EU," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Our protein-based vaccine was developed using an innovative approach to traditional technology and has demonstrated efficacy and safety in both adolescents and adults."

The authorization was based on data from the ongoing pediatric expansionof PREVENT-19, a pivotal Phase 3 trial of 2,247 adolescents aged 12 through 17 years across 73 sites in the U.S., to evaluate the safety, effectiveness (immunogenicity), and efficacy of Nuvaxovid. In the trial, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.

Preliminary safety data from the trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, and not considered related to the vaccine. Local and systemic reactogenicity was generally lower than or similar to adults, after the first and second dose. The most common adverse reactions observed were injection site tenderness/pain, headache, myalgia, fatigue, and malaise. There was no increase in reactogenicity in younger (12 to <15 years old) adolescents compared to older (15 to <18 years old) adolescents. No new safety signal was observed through the placebo-controlled portion of the study.

The EC granted CMA for Nuvaxovid to prevent COVID-19 in individuals aged 18 and over in December 2021. In addition to the EC's expanded CMA, Indiahas granted emergency use authorization in the 12 through 17 year-old population.

Authorization in the U.S.

NVX-CoV2373 has not yet been authorized for use in the U.S. and the trade name Nuvaxovid has not yet been approved by the U.S. Food and Drug Administration.

Important Safety Information

For additional information on Nuvaxovid, please visit the following websites:

About NVX-CoV2373NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

The Novavax COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2- 8 Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.

Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain.

About the NVX-CoV2373 Phase 3 TrialsNVX-CoV2373 continues being evaluated in two pivotal Phase 3 trials.

PREVENT-19 (thePRE-fusion protein subunitVaccineEfficacyNovavaxTrial | COVID-19) is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 with Matrix-M adjuvant in 29,960 participants 18 years of age and over in 119 locations inthe U.S.andMexico. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. In the trial, NVX-CoV2373 achieved 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in theNew England Journal of Medicine(NEJM).

The pediatric expansion of PREVENT-19 is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety, effectiveness, and efficacy of NVX-CoV2373 with Matrix-M adjuvant in 2,247 adolescent participants 12 to 17 years of age in 73 locations in the United States, compared with placebo. In the pediatric trial, NVX-CoV2373 achieved its primary effectiveness endpoint (non-inferiority of the neutralizing antibody response compared to young adult participants 18 through 25 years of age from PREVENT-19) and demonstrated 80% efficacy overall at a time when the Delta variant of concern was the predominant circulating strain in the U.S.Additionally, immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied.

PREVENT-19 is being conducted with support from the U.S. government, including the Department of Defense, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health at HHS. BARDA is providing up to$1.75 billionunder a Department of Defense agreement (# MCDC2011-001).

Additionally, a trial conducted in the U.K. with 14,039 participants aged 18 years and over was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published inNEJM.

About Matrix-M AdjuvantNovavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide and will soon be under review in the U.S. for use in adults, adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visitwww.novavax.comand connect with us on LinkedIn.

*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.

Forward-Looking StatementsStatements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, a COVID-seasonal influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax' plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax' global supply chain, additional worldwide authorizations of NVX-CoV2373 for adolescents, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, and the efficacy, safety and intended utilization of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at http://www.sec.gov and http://www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:InvestorsAlex Delacroix | 240-268-2022[emailprotected]

MediaAli Chartan | 240-720-7804[emailprotected]

SOURCE Novavax, Inc.

More:
Novavax Nuvaxovid COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17 - PR Newswire

NEWYou can now listen to Fox News articles!

President Obama's former senior adviser David Axelrod said that "fear and panic" over their midterm election chances were driving Democrats to grumble about President Biden.

Axelrod told CNN's "New Day" on Friday that the complaints from within his own party were partly from Democrats in Congress worried about losing to Republicans in the upcoming elections.

"Well, fear and panic iswhat's driving it, John [Berman].People are worried about themidterm elections, much of theclamor is coming from Capitol Hill, where, you know, manymembers are up for re-electionin November.So that's part of it," he stated.

CHICAGO, ILLINOIS - OCTOBER 18: David Axelrod, former advisor to President Barack Obama, asks Democratic presidential candidate South Bend, Indiana Mayor Pete Buttigieg questions during an event at the University of Chicago on October 18, 2019 in Chicago, Illinois. The event was hosted by the University of Chicago Institute of Politics. (Photo by Scott Olson/Getty Images)

DAVID AXELROD SEES BAD NEWS FOR BIDEN: THINGS LOOK OUT OF CONTROL AND HES NOT IN COMMAND'

The senior political commentator for the network went on to defend Democrats who wanted "vigorous" action from Biden over the "shocking" Supreme Court ruling overturning Roe v. Wade, while also defending Biden for having a tough job to handle.

"I have great sympathy forthe people in the White House.I was in the White House duringa similarly freighted time back in2010, it is not pleasant to beon the receiving end of all of these very helpful suggestions," Axelrod said. But he claimed Democrats were faulting Biden for not being politically aggressive when he ran on an opposing platform as a candidate.

"But, when Democrats choseJoe Biden, when Joe Biden waselected, he was elected for thevery things he's beingcriticized for.He was elected because he was considered a calm, conciliatoryfigure after the tumultuous years of Donald Trump," he argued.

President Joe Biden delivers remarks on the recent mass shootings from the White House on June 02, 2022 in Washington, DC. (Photo by Kevin Dietsch/Getty Images)

DAVID AXELROD URGES BIDEN TO SHOW HUMILITY AHEAD OF SOTU ADDRESS: PROCEED WITH CAUTION IF YOU BOAST RECORD

Axelrod went on to say that Biden's "done better than his numbers reflect" and that criticism from Democrats is mostly a result of Biden not acting quickly or aggressively enough.

But Axelrod himself has contributed to the negativity coming from within the Democratic Party.

Just last week, he told CNN's Jake Tapper that the economy was making Biden look weak. Last month, he earned the ire of "The View" co-host Joy Behar for telling the Times that the president's age was a "major" stumbling block to running in 2024. In response, Behar scolded the former White House adviser to "keep his mouth shut."

President Biden announces a ban on Russian oil imports, toughening the toll on Russia's economy in retaliation for its invasion of Ukraine, Tuesday, March 8, 2022, in the Roosevelt Room at the White House in Washington. (AP Photo/Andrew Harnik)

CLICK HERE TO GET THE FOX NEWS APP

According to that Times report published in June, Democrats outside the White House are questioning if President Biden run again in the 2024 election, citing his age and ineffective leadership reasons why he shouldn't.

Rep. Alexandria Ocasio-Cortez drew headlines when she dodged answering whether she'd support Biden running again, during a CNN interview.

A Fox News poll in June found 57% of voters view the president negatively.

Kristine Parks is an associate editor for Fox News Digital. Story tips can be sent to kristine.parks@fox.com.

Continue reading here:
David Axelrod tells CNN 'fear and panic' over midterms driving Democrat grumbling about Biden - Fox News

In a ridiculous new campaign ad released this week, Jerone Davison, a Black Republican in Arizona whos running for Congress, scares off what he calls Ku Klux Klan Democrats by brandishing an assault-style rifle.

Anybody arguing that todays Klan and todays Democrats are simpatico doesnt have good walking-around sense.

A Black man claiming he needs an AR-15 to keep a dozen Ku Klux Dems from invading his home may believe hes being clever, but really, hes just making an argument for putting would-be gun owners through a battery of cognitive tests. Because anybody arguing that todays Klan and todays Democrats are simpatico doesnt have good walking-around sense, to say nothing of good walking-around-with-a-gun sense.

But Davison must know that nonsense is more likely to make him attractive to the voters he wants to send him to the House, especially the kind of nonsense that implies that Black people are fools to vote blue.

Democrats like to say that no one needs an AR-15 for self-defense, that no one could possibly need all 30 rounds, we hear a voice say as Davison stands in his window with an AR-15-style rifle watching a whole klavern of Klansmen approach with a barbed bat and, for some reason, an assortment of garden tools. But when this rifle is the only thing standing between your family and a dozen angry Democrats in Klan hoods, you just might need that semi-automatic. And all 30 rounds.

Before we get to the main point, lets pause to point out the ads assumption that a dozen Klansmen looking to invade this Black mans home would themselves eschew AR-15s in favor of garden rakes and hatchets. In what part of Arizona would a homeowner have 30 rounds and a dozen Klansmen not have 360?

But thats the reality that the GOPs gun fetishists consistently ignore as they promote a political philosophy based on old Westerns: Theres nothing about being a so-called good guy with a gun that provides an advantage over a bad guy with the same.

On one level, Davisons false charge against Democrats is as flippant and reflexively dishonest as the claims that the Jan. 6, 2021, invasion of the U.S. Capitol was carried out not by Trump loyalists but by those opposed to Donald Trump. It doubles as an iteration of an older Republican argument: Because the Emancipation Proclamation, the preservation of the Union and a constitutional amendment ending slavery were Republican victories, Black people are fools to vote for anybody but Republicans but especially foolish to vote for Democrats, given that many were on the wrong side of the war, made up the bulk of the opposition to emancipation and, yes, included people who belonged to the Ku Klux Klan.

If theres a politician caught up in some kind of, er, klandal, safe money is on its being a Republican.

Had Republicans remained devoted to championing Black causes over Democrats objections, then puzzlement over Black peoples voting habits would be warranted. But to repeat a point previously made in this space, white Americans began their great migration out of the Democratic Party when it embraced civil rights, voting rights and anti-poverty programs. No Democrat running for the White House has won the white vote since.

At the same time, if theres a politician caught up in some kind of, er, klandal, safe money is on it being a Republican. Rep. Marjorie Taylor Greene, R-Ga., attended a white nationalist conference in Orlando, Florida, and Rep. Paul Gosar, R-Ariz., with whom Davison would represent Arizona if hes elected, sent a recorded greeting to the same conference. Years ago, Steve Scalise of Louisiana, now the second-highest-ranking Republican in the House, accepted an invitation from David Dukes campaign manager and political adviser to address a meeting of the European American Rights Organization, or EURO. As for Duke, who founded the Knights of the Ku Klux Klan decades before he founded EURO, he says hes a Republican, and he has run for office as such, greatly embarrassing Louisianas Republican Party leadership. (Duke's political history is also emblematic of the political shift mentioned above, in that he first ran for office (in 1979) as a conservative Democrat.)

Then there's Trump. When a coalition of white supremacist groups followed the Ku Klux Klan to Charlottesville, Virginia, in 2017, Trump declared that there were good people among them even after a woman protesting their evil presence was run over and killed. If Trump had thought the Klan was made up of Democrats, hed have said so.

Davisons ad is a reminder that Republicans rarely try to attract Black voters to the party; they try to shame and insult them into it. How could you possibly vote for a party that fought for slavery, they ask? As if Black people would be better off choosing the party thats looking to finish off the Voting Rights Act.

Its past time that Republican candidates stop insulting Black peoples intelligence and acting as if we cant separate the past from the present. Arguing that every Ku Klux Klan member is a Democrat because of what happened in the past makes about as much sense as arguing that Davisons peering out of a window with a rifle pointed upward makes him Malcolm X.

Original post:
Campaign ad criticizing KKK Democrats is nonsensical and insulting - MSNBC

President Joe Bidens economic agenda might be back from the dead. If the original proposal was Build Back Better, this is more like Build Back a Bit.

Democrats this week took the first formal step toward reviving a stripped-down version of the nearly $2 trillion plan that Senator Joe Manchin killed late last year. Majority Leader Chuck Schumer asked the Senate parliamentarian to review a proposed agreement that aims to reduce the cost of prescription drugs by allowing Medicare to negotiate prices directlya long-sought Democratic priority that Manchin supports. That is one major component of a deal Schumer and Manchin have been discussing that would include hundreds of billions of dollars to combat climate change along with deficit-slashing tax increases on the wealthy.

The deal could be ready for votes on the Senate floor by the end of this month, according to a Democrat familiar with the talks who described the development as major progress toward enacting a chunk of Bidens program before the midterm elections. Caveats abound: Schumer and Manchin have yet to complete either the tax or the climate portions of the bill, and the West Virginia centrist has abandoned negotiations before. With no Republican support, Democrats need the parliamentarian to determine whether their proposal can qualify for the process known as budget reconciliation, which would circumvent an expected filibuster and allow a bill to pass with a simple majority vote. A second Democratic aide, who like the first spoke anonymously to describe the delicate discussions, told me that a final deal would probably take several weeks and characterized the hopes for a vote before Congress breaks for its August recess as ambitious.

Read: Its not just Manchin

Yet the fact that the Schumer-Manchin talks have advanced even this far counts as a welcome surprise for Democrats, especially considering how acrimoniously the original Build Back Better negotiations collapsed in December. Manchin walked away after accusing the White House of putting his family at risk by singling him out in an otherwise anodyne statement describing the status of the discussions. In announcing his decision on Fox News, he further complained that the Democrats proposal was full of budget gimmicks and could worsen inflation. Because Manchin represented the crucial 50th vote in the evenly divided Senate, his departure ended Bidens hopes of delivering on a progressive agenda that initially included a federal paid-leave program, universal pre-kindergarten, free community college, and an extension of the presidents expanded child tax credit.

The negotiations remained dormant through the winter. There is no Build Back Better bill, Manchin told reporters in February. Its dead. But he and Schumer quietly began talking again in the spring, keeping their negotiations secret both to avoid the daily pestering of the Capitol Hill press corps and to prevent Democrats from getting their hopes up. Gone are many of the items on Bidens original wish list, as is the original $3.5 trillion price tag. The total revenue Schumer and Manchin now hope to generate through tax increases and drug-pricing reform is likely to be in the area of $1 trillion, with about $500 billion in new spending on climate and energy policies.

Any deal that Schumer and Manchin strike will probably win applause from the bulk of the Democratic Party, including progressives. A $1 trillion bill might seem paltry next to the dream of $3.5 trillion, but its a lot better than the nothing that most Democrats have expected to get for the past six months. The contours are fine, Adam Green, a co-founder of the Progressive Change Campaign Committee, told me about the potential deal. He said the climate piece was by far the most important aspect of the package for progressives, especially in light of last months Supreme Court decision limiting the EPAs ability to fight climate change. We cant reverse the Trump tax cuts if the planet disintegrates. The other two [proposals] are political winners, Green said of the drug-pricing reforms and tax increases. Climate change is just existential for the planet, and this might be our last chance.

Robinson Meyer: The Supreme Courts EPA ruling is going to be very, very expensive

Another sign that the negotiations are serious is that Senate Minority Leader Mitch McConnell tried to torpedo them last week by threatening to pull GOP support from a bipartisan high-tech manufacturing bill if the Democrats moved forward with the one-party reconciliation progress. Schumers move today suggests that at least for now, McConnells warning hasnt scared off Manchin.

As I wrote last year, the political advantage of Bidens economic agenda was always its size and ambition, because that meant with slim margins in Congress, it could withstand plenty of cuts and still represent a significant legislative accomplishment. That remains true today, perhaps even more so. An agreement on drug pricing, climate spending, and tax increases, combined with Bidens $1.9 trillion American Rescue Plan, the $1 trillion infrastructure law, and the recent bipartisan gun-safety compromise, would make the presidents legislative record look a lot more robust.

Politically, a scaled-down bill that passes close to the midterm elections, when it will be fresh in voters minds, might be just as beneficial to Democrats as a larger bill enacted months earlier. Each of the major components has clear constituencies. Lowering the cost of prescription drugs is a particular hit with seniors, a key voting bloc, and Democrats also plan to sell the change as a way to offset the impact of inflation. Combatting climate change is a priority of progressive and younger voters, whom Democrats need to turn out in November. And polls have long shown that tax increases on the wealthy are among the most broadly popular proposals in Bidens plan.

Members of Congress love their sports metaphors, and in that spirit, the emerging Schumer-Manchin proposal is less a Hail Mary pass than a long-field-goal attempt right before halftime. Substantively, none of the proposals would fully solve the problems they aim to address. The drug-pricing scheme is less ambitious than what Democrats initially wanted, and Manchin has already watered down some of the climate policies backed by progressives. Electorally, given persistent inflation and Bidens approval rating dipping into the 30s, maintaining the House majority may be impossible for Democrats (the Senate is another story). But taken as a whole, the package could help Democrats keep the score closeboth in their bid to deliver tangible results for their voters and in the battle for power in Congress this fall.

Link:
Democrats Try to Build Back (A Bit) Better - The Atlantic